Article
A pharmacodynamic model of erythropoietin therapy for uremic anemia.
Clinical pharmacology and therapeutics - 1 Jan 1992
Uehlinger D E, Gotch F A, Sheiner L B
Abstract excerpt
Fifty-seven patients receiving chronic high-flux hemodialysis began receiving recombinant alpha-human erythropoietin (rHuEPO). The mean initial rHuEPO dose used in 54 evaluable patients was 9963 +/- 4364 U/week; the final dose was 8972 +/- 4058 U/week. Treatment over a mean period of 154 +/- 40 days (84 to 224 days) resulted in an average increase in hematocrit from 24.7% +/- 3.7% to 32.5% +/- 4.4%. We present a...
Topics
- Anemia
- Dose-Response Relationship, Drug
- Erythrocyte Aging
- Erythrocytes
- Erythropoietin
- Female
- Genetic Variation
- Hematocrit
- Humans
- Male
- Recombinant Proteins
- Software